November is #PancreaticCancer Awareness month. We are very proud to be on the forefront of research for this devastating disease with several Phase 1 trials that show promise.?
NEXT Oncology
医院和医疗保健
SAN ANTONIO，TX 2,002 位关注者
A Phase 1 center dedicated to providing options for advanced cancer patients and advancing cancer research.
关于我们
NEXT Oncology, founded by Anthony W. Tolcher, M.D., FRCPC, is a Phase 1 center dedicated to providing options for advanced cancer patients and advancing cancer research. Dr. Tolcher’s passion for research and the community lays the foundation for an international brand committed to finding the next breakthrough. Dr. Anthony Tolcher is a medical oncologist and co-founder of NEXT. He is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option that includes clinical trials of new agents and therapies. Dr. Tolcher is proud that at NEXT Oncology the team scours the world to bring the best new agents back to our patients and centers. This is not a job for Dr. Tolcher, it is his passion.
- 网站
-
https://nextoncology.com
NEXT Oncology 的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 201-500 人
- 总部
- SAN ANTONIO，TX
- 类型
- 合营企业
- 创立
- 2018
- 领域
- cancer research、phase 1 clinical trials和oncology
地点
NEXT Oncology 员工
-
Aracely Cavazos
VP Regulatory Affairs & Administration at NEXT Oncology
-
Gina Mangold
Executive VP & COO at NEXT Oncology San Antonio
-
Anthony Tolcher
CEO, Founder and Director of Clinical Research at NEXT, San Antonio
-
Rachel K Branch
Financial Literacy Advocate, Past CEO of Trinity House of Love, Inc.
动态
-
We are delighted to be involved in the Phase 1 clinical trial for Aprea Therapeutics. From our CEO Anthony Tolcher: “The preliminary findings from ACESOT-1051 are promising and we are encouraged by the minimal toxicity in the patients treated so far.”?
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics | Aprea Therapeutics
ir.aprea.com
-
November is lung cancer awareness month and our colleague Alex Spira, MD, PhD, FACP, FASCO is leading the charge on advancing research.
Trial highlights potential next-gen biologic for lung cancer
https://www.europeanpharmaceuticalreview.com
-
Don't miss this update from Pyxis Oncology featuring Anthony Tolcher - Wednesday, November 20 at 4:30pm Eastern.
#PYXS will host an in-person and virtual event to discuss preliminary dose escalation data from the ongoing Phase 1 clinical trial evaluating PYX-201 in multiple types of solid tumors. The event will take place on Wednesday, November 20, 2024, at 4:30 p.m. ET at Venue 42 by Convene, located at 5 Times Square in New York City. Mark your calendars and register to attend live or virtually here: https://bit.ly/4e97No8
-
-
Today at Society for Immunotherapy of Cancer (SITC) - don't miss Shiraj Sen's late-breaking poster presentation.
1464?Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in patients with advanced cancers
jitc.bmj.com
-
We are proud to be at Society for Immunotherapy of Cancer (SITC) this week and are looking forward to a late-breaking poster presentation by our own Shiraj Sen on Saturday. Abstract Number?1464 Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in patients with advanced cancers